Trial Profile
Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Dec 2016
Price :
$35
*
At a glance
- Drugs CYD TDV (Primary)
- Indications Dengue
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
- 24 Jul 2012 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India.
- 29 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 11 Apr 2012 Additional lead trial centre identified as reported by Clinical Trials Registry - India.